Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Elizabeth

Showing results (171-180 of 178) with videos related to

Pageof 18
Sort By:
You have reached the last page of results.This site can display upto 178 results.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2018
Quantifying resilience of humans and other animalsMarten Scheffer, J Elizabeth Bolhuis, Denny Borsboom, et al.
Journal of Medicinal Chemistry|July 26, 2002
Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesityMichael H Block, Scott Boyer, Wayne Brailsford, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.
Molecular Cancer|July 13, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitorsJordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, et al.
Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.
Communications Biology|February 16, 2026
Integration of multiomic and multi-phenotypic data identifies biological pathways associated with physical fitnessAzar Alizadeh, John Graf, Matthew J Misner, et al.
Pageof 18

Showing results (171-180 of 178) with videos related to

Sort By:
Pageof 18
You have reached the last page of results.This site can display upto 178 results.
Proceedings of the National Academy of Sciences of the United States of America|October 31, 2018
Quantifying resilience of humans and other animalsMarten Scheffer, J Elizabeth Bolhuis, Denny Borsboom, et al.
Journal of Medicinal Chemistry|July 26, 2002
Discovery and optimization of a series of carbazole ureas as NPY5 antagonists for the treatment of obesityMichael H Block, Scott Boyer, Wayne Brailsford, et al.
British Journal of Cancer|April 3, 2026
Treatment monitoring by biomarker analysis in a Phase I dose-expansion study of AZD2811 for relapsed/refractory small-cell lung cancerMelissa L Johnson, Giulia Fabbri, Carmela Ciardullo, et al.
Leukemia & Lymphoma|July 16, 2021
A phase 1/2 study of the combination of acalabrutinib and vistusertib in patients with relapsed/refractory B-cell malignanciesGraham P Collins, Tracy N Clevenger, Kathleen A Burke, et al.
Journal of Medicinal Chemistry|November 28, 2017
Discovery and Optimization of Pyrrolopyrimidine Inhibitors of Interleukin-1 Receptor Associated Kinase 4 (IRAK4) for the Treatment of Mutant MYD88<sup>L265P</sup> Diffuse Large B-Cell LymphomaJames S Scott, Sébastien L Degorce, Rana Anjum, et al.
Molecular Cancer|July 13, 2023
BID expression determines the apoptotic fate of cancer cells after abrogation of the spindle assembly checkpoint by AURKB or TTK inhibitorsJordi Bertran-Alamillo, Ana Giménez-Capitán, Ruth Román, et al.
Molecular Cancer Therapeutics|December 4, 2020
AZD0364 Is a Potent and Selective ERK1/2 Inhibitor That Enhances Antitumor Activity in <i>KRAS</i>-Mutant Tumor Models when Combined with the MEK Inhibitor, SelumetinibVikki Flemington, Emma J Davies, David Robinson, et al.
Communications Biology|February 16, 2026
Integration of multiomic and multi-phenotypic data identifies biological pathways associated with physical fitnessAzar Alizadeh, John Graf, Matthew J Misner, et al.
Pageof 18